Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Its lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. The company's other drug candidate, Liposomal Bcl-2, is ready for the clinic where it would be evaluated in lymphoma and solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.